One possibility could be the administration of glucagon-like peptide-1 receptor (GLP-1R) agonists or dipeptidyl peptidase-4 (DPP-4) inhibitors, two incretin-based therapies commonly used for the treatment of type 2 diabetes mellitus due to their effects on body weight reduction. This evidence concerns the gene DPP4 and type 2 diabetes mellitus.